December 7, 2009:
GlycoMimetics Announces Two Oral Presentations on Lead Drug Candidate GMI-1070 at American Society of Hematology Annual Meeting October 20, 2009:
GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round September 2, 2009:
GlycoMimetics, Inc. Announces Commencement of Pilot Study in Patients of Lead Drug Candidate for Vaso-Occlusive Crisis of Sickle Cell Disease August 17th, 2009:
GlycoMimetics, Inc. Awarded NIH Grant to Study Drug Candidate in Diabetes July 24th, 2009: Nature Reviews: Drug Discovery Article Describes Design of Glycomimetic Compounds and Newly "Druggable" Disease Targets May 28th, 2009:
Dana-Farber Cancer Institute Presents Results of GlycoMimetics’ Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting March 26th, 2009:
GlycoMimetics, Inc. Completes Phase 1 Clinical Studies of Lead Drug Candidate; GMI-1070 Awarded Orphan Drug Designation by the FDA.
December 8th, 2008:
GlycoMimetics, Inc. Selected to Present Preclinical Data on Lead Drug Candidate at 50th Annual Meeting of the American Society of Hematology. September 5th, 2008:
GlycoMimetics, Inc. Commences Phase 1 Clinical Trial of Lead Drug Candidate. December 9th, 2007:
GlycoMimetics Presents Results of Lead Compound in Animal Models of Vaso-Occlusive Crisis at ASH. July 19th, 2007:
GlycoMimetics Highlights Advances in Lead Drug Candidate at International Conference.
June 23rd, 2006:
GlycoMimetics, Inc. Closes $15.4-million Series B.
September 2nd, 2005:
GlycoMimetics to Present New Data on Lead Compounds at International Symposium. |
